292 related articles for article (PubMed ID: 9443402)
1. BCL-X expression in multiple myeloma: possible indicator of chemoresistance.
Tu Y; Renner S; Xu F; Fleishman A; Taylor J; Weisz J; Vescio R; Rettig M; Berenson J; Krajewski S; Reed JC; Lichtenstein A
Cancer Res; 1998 Jan; 58(2):256-62. PubMed ID: 9443402
[TBL] [Abstract][Full Text] [Related]
2. Expression of BAX in plasma cell dyscrasias.
Renner S; Weisz J; Krajewski S; Krajewska M; Reed JC; Lichtenstein A
Clin Cancer Res; 2000 Jun; 6(6):2371-80. PubMed ID: 10873089
[TBL] [Abstract][Full Text] [Related]
3. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells.
Gauthier ER; Piché L; Lemieux G; Lemieux R
Cancer Res; 1996 Mar; 56(6):1451-6. PubMed ID: 8640839
[TBL] [Abstract][Full Text] [Related]
4. The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in multiple myeloma cells through transcriptional repression and down-regulation of Mcl-1.
Gojo I; Zhang B; Fenton RG
Clin Cancer Res; 2002 Nov; 8(11):3527-38. PubMed ID: 12429644
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization of myeloma plasma cells by an antisense-mediated downregulation of Bcl-2 protein.
van de Donk NW; Kamphuis MM; van Dijk M; Borst HP; Bloem AC; Lokhorst HM
Leukemia; 2003 Jan; 17(1):211-9. PubMed ID: 12529680
[TBL] [Abstract][Full Text] [Related]
6. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.
Chauhan D; Velankar M; Brahmandam M; Hideshima T; Podar K; Richardson P; Schlossman R; Ghobrial I; Raje N; Munshi N; Anderson KC
Oncogene; 2007 Apr; 26(16):2374-80. PubMed ID: 17016430
[TBL] [Abstract][Full Text] [Related]
7. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
8. Fas (APO-1/CD95)-mediated apoptosis is independent of bcl-2: a study with cell lines overexpressing bcl-2 and with bcl-2 transfected cell lines.
Gazitt Y; Hu WX
Int J Oncol; 1998 Jan; 12(1):211-20. PubMed ID: 9454907
[TBL] [Abstract][Full Text] [Related]
9. The Bcl-2 family protein inhibitor, ABT-737, has substantial antimyeloma activity and shows synergistic effect with dexamethasone and melphalan.
Trudel S; Stewart AK; Li Z; Shu Y; Liang SB; Trieu Y; Reece D; Paterson J; Wang D; Wen XY
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):621-9. PubMed ID: 17255285
[TBL] [Abstract][Full Text] [Related]
10. Analysis of histone deacetylase inhibitor, depsipeptide (FR901228), effect on multiple myeloma.
Khan SB; Maududi T; Barton K; Ayers J; Alkan S
Br J Haematol; 2004 Apr; 125(2):156-61. PubMed ID: 15059137
[TBL] [Abstract][Full Text] [Related]
11. Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.
Olejniczak SH; Hernandez-Ilizaliturri FJ; Clements JL; Czuczman MS
Clin Cancer Res; 2008 Mar; 14(5):1550-60. PubMed ID: 18316580
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and -independent pathways in cisplatin-resistant and -sensitive human ovarian cancer cell lines.
Henkels KM; Turchi JJ
Cancer Res; 1999 Jul; 59(13):3077-83. PubMed ID: 10397248
[TBL] [Abstract][Full Text] [Related]
13. Expression of Bcl-2 family proteins in advanced laryngeal squamous cell carcinoma: correlation with response to chemotherapy and organ preservation.
Trask DK; Wolf GT; Bradford CR; Fisher SG; Devaney K; Johnson M; Singleton T; Wicha M
Laryngoscope; 2002 Apr; 112(4):638-44. PubMed ID: 12150516
[TBL] [Abstract][Full Text] [Related]
14. Human melanoma cell lines selected in vitro displaying various levels of drug resistance against cisplatin, fotemustine, vindesine or etoposide: modulation of proto-oncogene expression.
Kern MA; Helmbach H; Artuc M; Karmann D; Jurgovsky K; Schadendorf D
Anticancer Res; 1997; 17(6D):4359-70. PubMed ID: 9494534
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of BCL-X(L) underlies the molecular basis for resistance to staurosporine-induced apoptosis in PC-3 cells.
Li X; Marani M; Mannucci R; Kinsey B; Andriani F; Nicoletti I; Denner L; Marcelli M
Cancer Res; 2001 Feb; 61(4):1699-706. PubMed ID: 11245486
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein mediates celecoxib-induced apoptosis in multiple drug-resistant cell lines.
Fantappiè O; Solazzo M; Lasagna N; Platini F; Tessitore L; Mazzanti R
Cancer Res; 2007 May; 67(10):4915-23. PubMed ID: 17510421
[TBL] [Abstract][Full Text] [Related]
17. Bcl-xL is expressed in ovarian carcinoma and modulates chemotherapy-induced apoptosis.
Liu JR; Fletcher B; Page C; Hu C; Nunez G; Baker V
Gynecol Oncol; 1998 Sep; 70(3):398-403. PubMed ID: 9790794
[TBL] [Abstract][Full Text] [Related]
18. The histone deacetylase inhibitor LBH589 is a potent antimyeloma agent that overcomes drug resistance.
Maiso P; Carvajal-Vergara X; Ocio EM; López-Pérez R; Mateo G; Gutiérrez N; Atadja P; Pandiella A; San Miguel JF
Cancer Res; 2006 Jun; 66(11):5781-9. PubMed ID: 16740717
[TBL] [Abstract][Full Text] [Related]
19. [Role of apoptosis-associated genes and caspase-3 in cisplatin-resistant human ovarian cancer cell lines].
Yang XK; Xing H; Zheng F; Gao QL; Wang W; Lu YP; Ma D
Zhonghua Fu Chan Ke Za Zhi; 2003 Mar; 38(3):158-61. PubMed ID: 12816691
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of apoptotic proteins causes multidrug resistance in renal carcinoma cells.
Scheltema JM; Romijn JC; van Steenbrugge GJ; Schröder FH; Mickisch GH
Anticancer Res; 2001; 21(5):3161-6. PubMed ID: 11848468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]